BRPI0917265A2 - tratamento de atrofia vaginal em mulheres com risco patológico de tumor - Google Patents

tratamento de atrofia vaginal em mulheres com risco patológico de tumor

Info

Publication number
BRPI0917265A2
BRPI0917265A2 BRPI0917265A BRPI0917265A BRPI0917265A2 BR PI0917265 A2 BRPI0917265 A2 BR PI0917265A2 BR PI0917265 A BRPI0917265 A BR PI0917265A BR PI0917265 A BRPI0917265 A BR PI0917265A BR PI0917265 A2 BRPI0917265 A2 BR PI0917265A2
Authority
BR
Brazil
Prior art keywords
women
tumor
treatment
vaginal atrophy
pathological risk
Prior art date
Application number
BRPI0917265A
Other languages
English (en)
Inventor
Alvaro Acebrón Fernández
Concepción Nieto Magro
Dolores Blanco Lousame
Jaime Moscoso Del Prado
Original Assignee
Italfarmaco Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41012001&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0917265(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Italfarmaco Sa filed Critical Italfarmaco Sa
Publication of BRPI0917265A2 publication Critical patent/BRPI0917265A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
BRPI0917265A 2008-08-07 2009-08-07 tratamento de atrofia vaginal em mulheres com risco patológico de tumor BRPI0917265A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES200802384A ES2344673B1 (es) 2008-08-07 2008-08-07 Uso de estriol en la preparacion de una formulacion farmaceutica parael tratamiento de atrofia vaginal en mujeres con riesgo de potologiatumoral.
PCT/EP2009/060307 WO2010015718A1 (en) 2008-08-07 2009-08-07 Treatment of vaginal atrophy in women with tumor pathology risk

Publications (1)

Publication Number Publication Date
BRPI0917265A2 true BRPI0917265A2 (pt) 2015-11-10

Family

ID=41012001

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0917265A BRPI0917265A2 (pt) 2008-08-07 2009-08-07 tratamento de atrofia vaginal em mulheres com risco patológico de tumor

Country Status (22)

Country Link
US (1) US9114143B2 (pt)
EP (1) EP2328589B1 (pt)
JP (1) JP6207118B2 (pt)
KR (1) KR101790652B1 (pt)
CN (1) CN102170886A (pt)
BR (1) BRPI0917265A2 (pt)
CA (1) CA2732877C (pt)
CL (1) CL2011000252A1 (pt)
CO (1) CO6351732A2 (pt)
CY (1) CY1120962T1 (pt)
DK (1) DK2328589T3 (pt)
ES (2) ES2344673B1 (pt)
HR (1) HRP20182020T1 (pt)
HU (1) HUE041377T2 (pt)
LT (1) LT2328589T (pt)
MX (1) MX336154B (pt)
PE (1) PE20110682A1 (pt)
PL (1) PL2328589T3 (pt)
PT (1) PT2328589T (pt)
RU (1) RU2504381C2 (pt)
SI (1) SI2328589T1 (pt)
WO (1) WO2010015718A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3787633A1 (en) * 2018-05-02 2021-03-10 Pantarhei Oncology B.V. Treatment of advanced estrogen receptor positive breast cancer
CN110151680A (zh) * 2019-04-10 2019-08-23 重庆医药高等专科学校 雌三醇凝胶产品及制备方法
CN114588252A (zh) * 2022-04-08 2022-06-07 暨南大学附属第一医院（广州华侨医院） 一种用于缓解阴道萎缩和干燥症的组合物及其应用

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1866M (fr) * 1961-04-07 1963-06-17 Vismara Francesco Spa Nouveaux éthers des hormones oestrogenes.
US4436738A (en) * 1982-03-15 1984-03-13 Mead Johnson & Company Stabilized estradiol cream composition
WO1985002092A1 (en) 1983-11-14 1985-05-23 Bio-Mimetics Inc. Bioadhesive compositions and methods of treatment therewith
US5719197A (en) * 1988-03-04 1998-02-17 Noven Pharmaceuticals, Inc. Compositions and methods for topical administration of pharmaceutically active agents
WO1991006289A1 (en) 1989-10-31 1991-05-16 Watson Laboratories, Inc. Mucoadhesive carrier for delivery of therapeutical agent
DE69014081T2 (de) 1989-10-31 1995-03-30 Columbia Laboratories, Inc., Miami, Fla. Mittel zur Feuchthaltung vaginalen Gewebes.
US5340586A (en) * 1991-04-12 1994-08-23 University Of Southern California Methods and formulations for use in treating oophorectomized women
US5543150A (en) 1993-09-15 1996-08-06 Columbia Laboratories, Inc. Method of progesterone delivery and affect thereof
IL110024A (en) * 1994-06-15 1998-04-05 Yissum Res Dev Co Controlled release oral drug delivery system containing hydrogel- forming polymer
US5667492A (en) 1994-10-07 1997-09-16 Columbia Laboratories, Inc. Use and composition of an anti-sexually transmitted diseases formulation
AT408067B (de) 1995-03-17 2001-08-27 Gebro Pharma Gmbh Pharmazeutische zusammensetzung zur topischen applizierung und verfahren zu ihrer herstellung
US5741525A (en) 1995-10-24 1998-04-21 Marshall University Research Corporation Vaginal pharmaceutical hydrogen peroxide composition
IT1275816B1 (it) 1995-10-27 1997-10-17 Montefarmaco Spa Composizioni farmaceutiche solide per uso vaginale
AU714797B2 (en) 1996-06-14 2000-01-13 Mcneil-Ppc, Inc. Moisture containing compositions that are spreadable onto and adherable to biomembranes, methods of making and use thereof
IT1284874B1 (it) 1996-08-02 1998-05-22 Farmigea Spa Complessi bioadesivi di polycarbophil e farmaci antifungini o antiprotozoari azolici
US5942243A (en) * 1996-11-12 1999-08-24 Polytherapeutics, Inc. Mucoadhesive compositions for administration of biologically active agents to animal tissue
CA2271843A1 (en) 1996-11-14 1998-05-22 Lipomedica Ehf. Topical formulations containing as a therapeutic active agent fatty acids or fatty alcohols or monoglyceride derivatives thereof for treating of mucosa infections
DE69819748T2 (de) 1997-09-12 2004-09-30 Columbia Laboratories (Bermuda) Ltd. Arzneimittel zur behandlung von dysmenorrhöe und verfrühten wehen
US6159491A (en) 1999-02-12 2000-12-12 Biovector Technologies, Inc. Prolonged release bioadhesive vaginal gel dosage form
PT1154793E (pt) 1999-02-26 2010-12-21 Novartis Vaccines & Diagnostic Utilização de bioadesivos e adjuvantes para a administração de antigénios nas mucosas
UA74168C2 (uk) 1999-10-05 2005-11-15 Коламбіа Леборетеріс (Бермуда) Лімітед Лікування ендометріозу або безпліддя, або покращення плідності та застосування бета-адренергічного агоніста для виробництва лікарського засобу
AU778498B2 (en) 1999-10-22 2004-12-09 Lif-Hlaup Ehf. Bio-Gels Pharmaceuticals Inc. Pharmaceutical composition for treatment of mucosal epithelial ulceration and/or erosion
AU2001282064B2 (en) 2000-08-03 2007-02-01 Antares Pharma Ipl Ag Novel composition for transdermal and/or transmucosal administration of active compounds that ensures adequate therapeutic levels
US20040092494A9 (en) * 2000-08-30 2004-05-13 Dudley Robert E. Method of increasing testosterone and related steroid concentrations in women
US7709026B2 (en) 2001-10-29 2010-05-04 Columbia Laboratories, Inc. Low concentration of peroxide for treating or preventing vaginal infections
TWI336627B (en) * 2003-05-23 2011-02-01 Organon Nv Drug delivery system,and use and manufacturing method thereof
ES2237298B1 (es) * 2003-07-16 2006-11-01 Italfarmaco, S.A. Formulaciones mucoadhesivas semisolidas.
BRPI0614625A2 (pt) 2005-08-12 2011-04-12 Drugtech Corp composição farmacêutica que compreende pelo menos um composto estrogênico, sistema de distribuição de estrogênio vaginal, uso de uma composição e kit que compreende uma pluralidade de cremes vaginais
US20090124584A1 (en) * 2005-12-16 2009-05-14 Lyle Corporate Development, Inc. Regeneration of vaginal tissue with non-systemic vaginal administration of estrogen
EP1971325A2 (en) * 2005-12-27 2008-09-24 Duramed Pharmaceuticals, Inc. Conjugated estrogen compositions, applicators, kits, and methods of making and use thereof
CN101405006A (zh) * 2006-01-20 2009-04-08 梨树医药公司 治疗萎缩性阴道炎的方法
EP1872775A1 (en) 2006-06-29 2008-01-02 Polichem S.A. Use of a hydrophilic matrix comprising a polyacrylic acid derivative, a cellulose ether and a disintegrant for the manufacture of a medicament for treating female genital disorders
WO2008089405A1 (en) 2007-01-19 2008-07-24 Neurosci, Inc. Composition of multiple hormones delivered vaginally in a single cream
ES2310968B1 (es) * 2007-06-25 2010-02-08 Italfarmaco, S.A. Uso de estriol en bajas dosis.

Also Published As

Publication number Publication date
SI2328589T1 (sl) 2019-02-28
KR101790652B1 (ko) 2017-11-20
US9114143B2 (en) 2015-08-25
CA2732877A1 (en) 2010-02-11
CA2732877C (en) 2017-04-18
CN102170886A (zh) 2011-08-31
ES2344673A1 (es) 2010-09-02
RU2504381C2 (ru) 2014-01-20
PE20110682A1 (es) 2011-09-28
DK2328589T3 (en) 2018-12-10
RU2011108548A (ru) 2012-09-20
HUE041377T2 (hu) 2019-05-28
ES2344673B1 (es) 2011-05-03
WO2010015718A1 (en) 2010-02-11
HRP20182020T1 (hr) 2019-01-25
MX336154B (es) 2016-01-11
CL2011000252A1 (es) 2011-11-18
CY1120962T1 (el) 2019-12-11
JP2011529951A (ja) 2011-12-15
JP6207118B2 (ja) 2017-10-04
KR20110045041A (ko) 2011-05-03
MX2011001382A (es) 2011-03-29
CO6351732A2 (es) 2011-12-20
PL2328589T3 (pl) 2019-05-31
PT2328589T (pt) 2018-12-18
ES2700614T3 (es) 2019-02-18
LT2328589T (lt) 2019-01-10
EP2328589A1 (en) 2011-06-08
US20110183950A1 (en) 2011-07-28
EP2328589B1 (en) 2018-09-19

Similar Documents

Publication Publication Date Title
BRPI0906099A2 (pt) "método de tratamento do câncer em um indivíduo"
EP2361117A4 (en) PHOTOTHERMIC TREATMENT OF SOFT TISSUE
PL2426148T3 (pl) Przeciwciało anty-IL-3RA do stosowania w leczeniu nowotworu krwi
BRPI1008566A2 (pt) métodos e composições para o diagnóstico e tratamento de câncer
BRPI0821779A2 (pt) tratamento terapêutico de câncer
BRPI1008564A2 (pt) métodos e composições para o dignóstico e tratamento de câncer
BRPI0912683A2 (pt) tratamento de tumores metastáticos
BRPI0911112A2 (pt) composições e métodos para o tratamento do câncer de mama
BRPI0815551A2 (pt) Tratamento através de hucbc de doença beta-amiloide
PL2614832T3 (pl) Diagnostyka i leczenie stanu przedrzucawkowego
EP2385114A4 (en) CANCER TREATMENT DIAGNOSIS WITH ANTI-TM4SF20 ANTIBODY
BRPI0817045A2 (pt) Tratamento de condições estrogênio-dependentes em mulheres pré-menopáusicas
BR112014012495A2 (pt) método in vitro, kit, inibidor de egfr e método de tratamento de pacientes afetados com câncer
BRPI0812932A2 (pt) Composições e métodos de tratar câncer
EP2094866A4 (en) DIAGNOSIS AND TREATMENT OF BREAST CANCER
DK2147122T3 (da) Enzymatisk kræftbehandling
GB0700972D0 (en) Treatment of inflammatory disease
DK3000467T3 (da) Behandling med neratinib mod brystkræft
GB201107350D0 (en) Topical treatment of skin infection
IL210938A0 (en) Kit for the treatment of onychomycosis
HRP20182020T1 (hr) Liječenje atrofije vagine kod žena u opasnosti od tumorske patologije
EP2377891A4 (en) DIAGNOSIS AND TREATMENT OF CANCER USING ANTI-LGR7 ANTIBODY
GB0720976D0 (en) Treatment of inflammatory disease
GB201003527D0 (en) VHZ for diagnosis and treatment of cancer
GB0901837D0 (en) Cancer diagnosis and treatment

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL